Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Tempus AI, Inc. Class A (TEM)
NASDAQ:TEM
RESEARCH TOOLSreports
Holding TEM?
Track your performance easily
TEM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$22.89 - $43.88
Previous Close$39.76
Volume1.04M
Average Volume (3M)1.97M
Market Cap
$6.55B
Enterprise Value$6.94B
Total Cash (Recent Filing)$94.90M
Total Debt (Recent Filing)$485.20M
Price to Earnings (P/E)―
Beta-12.19
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. Volume1,967,119
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/Revenue47.62
Enterprise Value/Gross Profit24.27
Enterprise Value/Ebitda-170.95
Forecast
1Y Price Target
$45.29Price Target Upside23.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Tempus AI, Inc. Class A News
Bulls Say, Bears Say
Bulls Say
AI And DataTempus AI is a unique platform company that sits at the intersection of healthcare and data/AI, focused on creating intelligent diagnostics for precision medicine.
Genomics GrowthOncology menu breadth, scaled lab infrastructure, and ample runway for wider payor coverage bode well for TEM’s genomics growth.
Market ReachTempus is now connected to over 50% of the oncologists in the US.
Bears Say
Cash BurnTempus is burning through cash, and its ability to achieve profitability and turn cash-flow-positive is uncertain.
Financial PerformanceDespite a sufficient current cash balance, Tempus's ability to achieve profitability and turn cash-flow-positive remains uncertain.
Regulatory And Legal RisksSignificant regulatory and legal risks exist in terms of reimbursement for its Dx menu, for the novel and unproven ‘AI Algorithms’ business, and for patient healthcare data privacy.
---
Ownership Overview
49.05% Insiders
0.00% Mutual Funds
0.36% Other Institutional Investors
50.59% Public Companies and
Individual Investors
TEM FAQ
What was Tempus AI, Inc. Class A’s price range in the past 12 months?
Tempus AI, Inc. Class A lowest stock price was $22.89 and its highest was $43.88 in the past 12 months.
What is Tempus AI, Inc. Class A’s market cap?
Currently, no data Available
When is Tempus AI, Inc. Class A’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Tempus AI, Inc. Class A’s earnings last quarter?
Currently, no data Available
Is Tempus AI, Inc. Class A overvalued?
According to Wall Street analysts Tempus AI, Inc. Class A’s price is currently Undervalued.
Does Tempus AI, Inc. Class A pay dividends?
Tempus AI, Inc. Class A does not currently pay dividends.
What is Tempus AI, Inc. Class A’s EPS estimate?
Tempus AI, Inc. Class A’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tempus AI, Inc. Class A have?
Tempus AI, Inc. Class A has 159,788,820 shares outstanding.
What happened to Tempus AI, Inc. Class A’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Tempus AI, Inc. Class A?
Currently, no hedge funds are holding shares in TEM
---
Tempus AI, Inc. Class A Stock Smart Score
Company Description
Tempus AI, Inc. Class A
Tempus AI endeavors to unlock the true power of precision medicine by creating Intelligent Diagnostics through the practical application of artificial intelligence in healthcare. Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal. To accomplish this, we built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Our proprietary technology has allowed us to amass what we consider to be one of the largest libraries of clinical and molecular oncology data in the world. We have launched a suite of different products derived from our Platform, which have gained significant traction over the past five years. To date, our offerings have been used by approximately 95% of the largest public pharmaceutical companies.
---
TEM Stock 12 Month Forecast
Average Price Target
$45.29
▲(23.74% Upside)
Technical Analysis
Best Analysts Covering TEM
1 Year
1 Year Success Rate
1/1 ratings generated profit
1 Year Average Return
+15.20%
initiated a buy rating 2 months ago
Copying Ryan MacDonald's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +15.20% per trade.
---